Our previous in vivo study in YG8R mice demonstrated that 30% of wildtype donor cell engraftment was sufficient to fully rescue the FRDA phenotype, and we obtained up to 55.9% of FXN of gene editing efficiency in patients’ CD34+ HSPCs, suggesting that this approach could reach therapeutic threshold for FRDA. Here, FXN is linked to Friedreich ataxia.